ACRO Biomedical Q2 net loss widens to $21,356; operating expenses rise to $17,554
ACBM•Q2 loss widens as expenses rise and revenue stays at zero
ACRO Biomedical posted a net loss of $21,356 for the quarter ended June 30, 2026, widening from $15,562.
Operating expenses climbed to $17,554 from $13,614, mainly on general and administrative costs and public-company professional fees.
Interest expense to two minority stockholders rose to $3,802 from $1,948; the company reported no revenue.
Cash was $3,648 at June 30, 2026, while the working capital deficit widened to $444,789 from $386,964 at Dec. 31, 2025.
Management said it had no sales since Dec. 31, 2022, and continues to rely on minority-stockholder advances for funding.
